Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

argenex SE ARGX

Healthcare — Biotechnology
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
62,300.00
Revenue
5,329.05
Net Income
1,600.81
Free Cash Flow
1,378.46
Net Debt
(3,584.00)
Current Ratio
5.12
Debt/Equity
0.00
P/E ratio
35.73
P/S ratio
11.58
P/B ratio
7.33
Past 5Y EPS Growth
(17.05%)
This Y EPS Growth
47.23%
Next Y EPS Growth
33.54%
Next 5Y EPS Growth
35.46%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 ‡‡‡‡‡
2025 ‡‡‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 2,048.84 1,499.94 3,491.29 3,584.00
Receivables 499.27 909.10 1,657.06 1,941.00
Inventory 310.55 407.23 473.53 371.00
Other 1,131.00 1,878.89 948.75 1,600.00
4,123.74 4,883.10 6,899.10 8,068.00
2023 2024 2025 Q'26
Payables 414.01 649.99 1,267.14 1,515.00
ST’ Debt — — — —
Other — — — —
422.99 669.92 1,320.19 1,575.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 1,313.00 1,542.00 — —
—
’25 807.00 967.00 1,151.34 1,322.71
4,248.05
’24 412.51 489.43 588.88 761.22
2,252.04
’23 229.76 281.04 339.84 417.96
1,268.59
’22 31.48 85.18 146.49 182.12
445.27
’21 178.57 464.71 7.11 33.68
539.42
’20 25.81 25.16 — 17.33
64.91
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 — 651.00 — —
—
’25 — 362.00 — 685.19
685.19
’24 — (124.66) — (82.75)
(82.75)
’23 — (285.44) — (420.33)
(420.33)
’22 — (494.51) — (862.81)
(862.81)
’21 — (225.07) — (606.81)
(606.81)
’20 — (147.43) — (256.88)
(398.46)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 — 643.00 — —
—
’25 — 313.00 — 573.51
573.51
’24 — (146.97) — (151.05)
(151.05)
’23 — (285.91) — (464.14)
(464.14)
’22 — (494.70) — (966.63)
(966.63)
’21 — (348.50) — (728.25)
(728.25)
’20 — (148.17) — (256.88)
(403.60)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 5.52 7.32 — —
—
’25 2.58 3.74 5.18 8.02
19.57
’24 (1.04) 0.45 1.39 11.79
12.78
’23 (0.52) (1.69) (1.25) (1.68)
(5.16)
’22 (4.36) (3.81) (4.26) (0.70)
(13.05)
’21 (0.81) 1.24 (4.40) (4.76)
(7.99)
’20 (2.06) (5.31) — (8.40)
(13.30)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 249.50 327.73 349.86 510.06 — — —
Low Price
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 407.93 550.76 644.97 934.62 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 843 1,148 1,599 1,863 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.53 1.11 1.41 2.28 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 445.27 1,268.59 2,252.04 4,248.05 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 93.39% 90.71% 89.91% 89.39% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (729.31) (304.50) 85.18 1,278.61 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (163.79%) (24.00%) 3.78% 30.10% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (720.34) (425.05) (21.65) 1,053.81 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 104.34 111.31 17.53 28.10 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.19 22.19 37.62 69.31 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (13.05) (5.16) 13.92 21.08 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.87) (7.35) (1.38) 11.18 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.91) (0.77) (1.14) (1.82) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.78) (8.12) (2.52) 9.36 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 51.74 71.67 91.86 119.47 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 54.38 57.17 59.86 61.30 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 44.69 39.97 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 45.65 17.17 16.35 12.13 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.22 5.32 6.70 7.04 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.88 15.56 15.68 11.31 ‡‡‡‡ ‡‡‡‡ ‡‡‡
EV/Sales
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (8.90) (8.06) (30.69) 81.68 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (862.81) (420.33) (82.75) 685.19 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (103.82) (43.81) (68.30) (111.68) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (966.63) (464.14) (151.05) 573.51 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,471.92 3,700.74 4,213.19 5,578.92 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.70 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (789.04) (2,048.84) (1,499.94) (3,491.29) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,813.70 4,097.51 5,498.28 7,323.09 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (23.71%) (7.69%) 15.51% 17.36% — — —
ROA
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (22.24%) (12.97%) (0.34%) 17.19% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (26.54%) (8.54%) 17.36% 20.15% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Argenx SE (ARGX), a leader in antibody therapies for immunology, has transformed from a cash-burning biotech to a revenue powerhouse since Vyvgart’s 2021 FDA approval for myasthenia gravis. Revenues exploded from €64.9 million in 2020 to €2.25 billion in 2024 (+77% YoY), fueled by U.S. launches, CIDP expansions, and the subcutaneous version, with revenue per share surging to €37.62 and per employee hitting €1.41 million despite workforce growth. Analyst projections forecast €4.27 billion in 2025 (+90%), scaling to €7.17 billion by 2027, tightly correlated with historical stock peaks like 2024’s $645 high.

Profitability flipped dramatically in 2024, with EBT turning €85 million positive from -€304 million prior year, EPS at €13.92, and gross margins near 90%, backed by a €1.5 billion net cash position and ROE of 17.4%. Forecasts show net income reaching €2.63 billion by 2027 (EPS €39.87), with free cash flow per share positive at €5.10 in 2025, de-risking the balance sheet amid pipeline advances like empasiprubart.

Trading at 16.3x P/S (down from 143x in 2020), ARGX’s recent close aligns with the low end of analyst targets implying 22% average upside to 60% high, justified by 40-90% CAGR ahead. While biotech risks like trial delays persist, Vyvgart expansions and phase 3 assets position ARGX for 2-3x potential— a compelling growth story for quantitative investors.

Read full commentary →

argenex SE (ARGX) Latest News

News by impact score

Fine-tune

2 Sep

3 www.fool.com, 5:04 AM
Argenx SE has achieved 18 consecutive quarters of sales growth, prompting assessment of whether its biotech stock remains undervalued. Sustained sales growth supports ongoing positive sentiment without indicating transformative new developments.

28 Aug

3 www.pharmavoice.com, 5:16 AM
Argenx SE rose to become one of Europe's most valuable biotechs on the strength of a single drug; its new CEO now prepares the company for subsequent growth initiatives. New CEO transition follows single-product success and may influence strategic direction without guaranteed fundamental change to company trajectory.

27 Aug

4 , 1:08 PM
Argenx completes acquisition of Forte Biosciences. Acquisition completion signals major strategic expansion with potential to shift Argenx trajectory and investor views.

4 , 8:50 AM
argenx SE completes acquisition of Forte Biosciences, Inc. Completed acquisition marks major strategic expansion altering argenx SE competitive positioning and growth trajectory.

3 , 8:15 PM
argenx (ENXTBR:ARGX) released information requiring investor attention. Company developments carry moderate potential to influence operations and market views.

26 Aug

4 www.fool.com, 5:06 AM
Argenx secured another Phase 3 trial success that points to stronger long-term growth prospects than Wall Street currently prices in. Phase 3 win advances pipeline toward approval and materially lifts future revenue outlook.

21 Aug

4 , 8:53 PM
argenx SE (ARGX) succeeded in its Phase 3 Myositis trial despite a subgroup miss that raises questions on result implications. Phase 3 trial success advances argenx myositis program toward approval and revenue growth.

18 Aug

4 , 12:01 PM
argenex SE reported positive Phase III data on Vyvgart Hytrulo, resulting in a stock price increase. Positive Phase III results for Vyvgart Hytrulo signal major progress toward approval and revenue expansion for argenex SE.

4 , 10:54 AM
Argenx myositis data strengthens efgartigimod outlook according to Morgan Stanley. Positive myositis data and analyst endorsement improve efgartigimod commercial prospects and argenx valuation trajectory.

4 , 2:10 AM
argenx SE shares rose 11.5% after positive Phase 3 data on its autoimmune myositis treatment, with further pipeline and commercialization steps ahead. Positive Phase 3 readout for a lead candidate can materially advance regulatory approval prospects and revenue potential.

17 Aug

4 , 3:00 PM
Argenx SE (ARGX) stock hits record highs on prospects for expanded approval of its lead drug Vyvgart, signaling potential for larger market reach and revenue growth. Expanded approval prospects for flagship drug could drive major revenue gains and shift company trajectory.

4 , 2:04 PM
Argenx SE stock heads for a record high after its blockbuster drug secures another win. Blockbuster drug success drives major gains in Argenx SE valuation and outlook.

4 www.clinicaltrialsarena.com, 11:51 AM
Argenx SE (ARGX) stock rises after Phase III win in autoimmune myositis. Phase III success in autoimmune myositis strengthens argenx pipeline and drives major stock gains.

4 investorshub.advfn.com, 10:53 AM
argenx SE's Phase 3 ALKIVIA trial met its primary endpoint in autoimmune myositis. Phase 3 success in autoimmune myositis supports regulatory approval prospects and revenue expansion for argenx.

4 , 10:30 AM
Argenx SE (ARGX) breaks out on another multibillion-dollar opportunity for Vyvgart. New multibillion-dollar opportunity for Vyvgart signals major revenue growth potential for ARGX.

4 www.marketbeat.com, 10:03 AM
argenx VYVGART met its Phase III primary endpoint in autoimmune myositis and will pursue an IMNM regulatory filing. Successful Phase III outcome expands VYVGART addressable market and advances regulatory timeline.

4 , 9:43 AM
Argenx's Vyvgart achieved another success, driving shares sharply higher. Vyvgart win signals major product advance that can shift company trajectory and investor sentiment.

4 www.biopharmadive.com, 8:12 AM
Argenx SE stock jumps after positive Phase 3 data for blockbuster drug Vyvgart. Positive Phase 3 results for key drug Vyvgart signal major revenue growth and strengthened market position for Argenx.

4 , 6:00 AM
argenx and Zai Lab report positive topline results from Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis. Positive Phase 3 results advance efgartigimod toward potential new approval and revenue growth.

4 , 1:00 AM
argenx SE announced positive topline results from the Phase 3 ALKIVIA trial of Efgartigimod in autoimmune myositis. Positive Phase 3 trial success for Efgartigimod opens path to new approval and revenue in autoimmune myositis.

11 Aug

4 , 2:35 PM
Argenx agrees to buy Forte Biosciences while hedge funds favor ARGX over FBRX. Acquisition constitutes a major strategic move likely to alter argenx trajectory and investor sentiment.

10 Aug

4 , 6:11 PM
argenx SE (ARGX) is considering an acquisition of Forte Biosciences. Potential acquisition of Forte Biosciences marks a major strategic move that could alter argenx trajectory.

6 Aug

4 , 7:48 AM
argenx SE has commenced a tender offer to acquire Forte Biosciences, Inc. Acquisition of Forte Biosciences marks a major strategic expansion for argenx SE.

4 Aug

4 , 11:35 AM
Argenx SE prepares to demonstrate Vyvgart’s efficacy in broader autoimmune diseases. Potential expansion of Vyvgart into additional autoimmune indications may significantly boost Argenx revenue and market position.

3 , 12:00 PM
Argenx (ARGX) is presented as a new buy stock on the back of positive pipeline progress, upcoming catalysts, and favorable market positioning. Buy recommendation may lift short-term sentiment and trading volume but is unlikely to alter long-term fundamentals.

30 Jul

4 www.barchart.com, 10:15 AM
Significant price movement occurred in Forte Biosciences stock ahead of Argenx SE's acquisition announcement. Argenx SE acquisition announcement signals major strategic move likely to alter company trajectory and investor sentiment.

29 Jul

4 , 3:45 AM
argenx commits $2.2 billion via deal with Forte Biosciences to advance vitiligo therapy, directly affecting ARGX stock trajectory and competitive positioning. Major capital allocation to new therapeutic program constitutes significant strategic move with direct long-term valuation impact.

4 , 12:26 AM
Forte Biosciences agrees to argenx takeover as tender offer nears. Argenx executes major acquisition of Forte Biosciences via agreed takeover.

28 Jul

4 www.pharmaceutical-technology.com, 5:35 AM
argenx SE has signed an agreement to buy Forte Biosciences for $2.2 billion. The $2.2 billion acquisition of Forte Biosciences constitutes a major strategic move that could significantly alter argenx SE's trajectory.

4 www.hospitalmanagement.net, 5:35 AM
argenx SE signs agreement to acquire Forte Biosciences for $2.2 billion. The $2.2 billion acquisition marks a major strategic expansion likely to shift argenx trajectory and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us